Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Sonoma Pharmaceuticals ( (SNOA) ) just unveiled an announcement.
Sonoma has terminated its exclusive agreement with EMC Pharma due to EMC’s failure to meet minimum purchase requirements, allowing Sonoma to resume direct sales of its dermatological and eye care products in the U.S. This decision is part of the company’s strategy to enhance its market presence, despite potential risks and uncertainties that could affect its future financial performance.
See more data about SNOA stock on TipRanks’ Stock Analysis page.